Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polyethylene Glycol Losenatide in Type 2 Diabetes
NCT05611684Phase 4Recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Nanjing First Hospital. Started Jun 2022; status: recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05611684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611684.